Table 6.
ROC analysis of the prognostic accuracy of SIRI-PLR for OS, CSS, and MFS in training and validation cohorts.
| Model | AUC (95% CI) | Sensitivity % | Specificity % | Youden index | Positive likelihood ratio | Negative likelihood ratio |
|---|---|---|---|---|---|---|
| Training cohort | ||||||
| OS | ||||||
| Model A | 0.836 (0.784–0.889) | 78.49 | 82.53 | 0.610 | 4.49 | 0.26 |
| Model B | 0.819 (0.765–0.874) | 67.74 | 86.14 | 0.539 | 4.89 | 0.37 |
| SIRI-PLR | 0.681 (0.613–0.748) | 54.84 | 74.70 | 0.295 | 2.17 | 0.60 |
| CSS | ||||||
| Model C | 0.858 (0.808–0.908) | 68.49 | 90.32 | 0.588 | 7.08 | 0.35 |
| Model D | 0.842 (0.783–0.900) | 72.60 | 84.95 | 0.576 | 4.82 | 0.32 |
| SIRI-PLR | 0.663 (0.591–0.734) | 82.19 | 36.83 | 0.263 | 1.47 | 0.48 |
| MFS | ||||||
| Model E | 0.799 (0.742–0.856) | 68.32 | 86.54 | 0.519 | 4.15 | 0.37 |
| Model F | 0.782 (0.724–0.839) | 78.22 | 62.66 | 0.409 | 2.10 | 0.35 |
| SIRI-PLR | 0.613 (0.543–0.684) | 47.52 | 71.52 | 0.190 | 1.67 | 0.73 |
| Validation cohort | ||||||
| OS | ||||||
| Model G | 0.819 (0.764–0.873) | 67.06 | 84.13 | 0.512 | 4.23 | 0.39 |
| Model H | 0.777 (0.720–0.833) | 87.06 | 57.67 | 0.447 | 2.06 | 0.22 |
| SIRI-PLR | 0.708 (0.639–0.777) | 71.76 | 61.90 | 0.334 | 1.88 | 0.46 |
| CSS | ||||||
| Model I | 0.830 (0.771–0.889) | 66.67 | 85.10 | 0.518 | 4.47 | 0.39 |
| Model J | 0.802 (0.740–0.864) | 78.79 | 70.19 | 0.490 | 2.64 | 0.30 |
| SIRI-PLR | 0.716 (0.642–0.789) | 75.76 | 60.10 | 0.359 | 1.90 | 0.40 |
| MFS | ||||||
| Model K | 0.761 (0.699–0.824) | 71.11 | 71.20 | 0.423 | 2.47 | 0.41 |
| Model L | 0.742 (0.679–0.805) | 66.67 | 75.00 | 0.417 | 2.67 | 0.44 |
| SIRI-PLR | 0.643 (0.572–0.715) | 58.89 | 65.22 | 0.241 | 1.69 | 0.63 |
OS, overall survival; CSS, cancer-specific survival; MFS, metastatic-free survival; SIRI-PLR, systemic inflammation response index- platelet-to-lymphocyte ratio; AUC, area under the curve.
Model A = age + hydronephrosis + SIRI-PLR + tumor size + pT + N stage + adjuvant therapy.
Model B = age + hydronephrosis + tumor size + pT + N stage + adjuvant therapy.
Model C = SIRI-PLR + tumor size + tumor site + pT + N stage + LVI + adjuvant therapy.
Model D = tumor size + tumor site + pT + N stage + LVI + adjuvant therapy.
Model E = hydronephrosis + SIRI-PLR + pT + N stage + adjuvant therapy.
Model F = hydronephrosis + pT + N stage + adjuvant therapy.
Model G = SIRI-PLR + tumor site + pT + N stage.
Model H = tumor site + pT + N stage.
Model I = SIRI-PLR + pT + N stage + adjuvant therapy.
Model J = pT + N stage + adjuvant therapy.
Model K = SIRI-PLR + pT + N stage + tumor grade.
Model L = pT + N stage + tumor grade.